NanoViricides, Inc. (NNVC.PK) Receives Notification That Clinical Coordinators Have Been Appointed by the European Medicines Agency to Review the Company's Upcoming DengueCide Orphan Drug Designation Application
7/22/2013 9:53:33 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
WEST HAVEN, Conn.--(BUSINESS WIRE)--NanoViricides, Inc. (OTC BB: NNVC) (the "Company") announced today that it has been notified that the Committee on Orphan Medicinal Products (COMP) of the European Medicine Agency (EMA) has appointed a team of clinical coordinators for the purpose of reviewing the Company’s upcoming orphan drug designation application for DengueCide™, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.
Help employers find you! Check out all the jobs and post your resume.
comments powered by